Medsafe reviews first application for oral GLP-1 weight-loss tablet
仅事实

Medsafe reviews first application for oral GLP-1 weight-loss tablet

摘要

New Zealand's regulator Medsafe is assessing an application for an oral GLP-1 medication, the tablet version of Wegovy approved in Australia, with a target assessment period of about 75 working days.

Medsafe has received an application for oral tablets of the GLP-1 weight-loss drug Wegovy, submitted under one of the agency's reliance pathways that allow it to use overseas data to shorten approval timelines. The regulator said it aims to complete an initial assessment within roughly 75 working days, although the total time may extend depending on the pharmaceutical company's responses and additional evidence required.

The agency will evaluate the submission to ensure the product meets international standards for safety, quality and efficacy before granting approval. No other weight-loss medicines are currently under consideration.

Dr Prabani Wood, medical director of the Royal New Zealand College of General Practitioners, noted that a daily tablet could provide an alternative for people who prefer not to use injections. She cautioned that approval does not guarantee funding or universal access, adding that equitable availability is essential.

"There’s evidence these drugs are effective in helping people lose weight, and it’s important to frame obesity as a disease rather than a choice," Wood said.

She also highlighted the lack of long-term safety and effectiveness data and called for policymakers to address the underlying causes of obesity.

Valentina Florez-Betancur, a New Zealand resident using self-funded GLP-1 therapy, reported significant weight loss with the injectable form and said she would consider switching to a tablet once it is approved locally.

"The pill for many GLP-1 users is more of a maintenance option rather than a starter," she told 1News.

Medsafe’s reliance pathway could halve the usual approval timeframe, potentially bringing the oral formulation to New Zealand patients sooner than a standard review process.

来源

1News

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。